What the evidence says about medicinal cannabis for pain, anxiety and sleep
Nielsen
Medicinal cannabis use has increased rapidly in recent years in Australia. Since access pathways were expanded in 2016, more than 700,000 prescription approvals have been issued.
The vast majority of medicinal cannabis products on the market have not been registered on the Australian Register of Therapeutic Goods. But medical practitioners can apply to the Therapeutic Goods Administration (TGA) for approval to prescribe them to patients.
Data shows the three most-common conditions for which scripts are approved are chronic pain, anxiety and sleep disorders.
Although many patients report benefits, professional bodies and regulators have raised concerns about whether prescribing is outpacing the evidence.
So what does the evidence actually say? Does medicinal cannabis work for the conditions for which it’s most commonly prescribed?
Medicinal cannabis for pain
Medicinal cannabis refers to cannabis products that are legally prescribed to treat a medical condition. This can be the plant itself, or natural compounds extracted from the plant. Some compounds similar to or the same as those found in cannabis (for example, dronabinol and nabilone) are made in a lab.
Two of the most common compounds in the plant are THC (tetrahydrocannabinol) and CBD (cannabidiol), known as cannabinoids.
These are commonly found at various concentrations in medicinal cannabis products that come in forms including oils, capsules, dried flower (used in a vaporiser), sprays and gummies.
Chronic pain is the most common reason for medicinal cannabis use. But as we’ve written in a previous article, research shows only modest benefits, with limited improvements in pain and physical functioning.
The TGA says there’s limited evidence medicinal cannabis provides clinically significant pain relief for many conditions, and should only be tried if other standard therapies haven’t helped.
Does medicinal cannabis work for anxiety?
Besides chronic pain, a growing number of people are now turning to medicinal cannabis for anxiety.
Multiple reviews have examined whether it works for this purpose and have come to similar conclusions. For THC-based products the evidence is mixed, with some patients finding relief, while others report their symptoms are worse.
There’s emerging evidence for CBD, but it’s too soon to recommend medical cannabis as a first-line treatment for anxiety. So far, studies of CBD in anxiety have been small, only measured effects under experimental conditions designed to induce stress, had no comparison group, or only tested a one-off dose.
Because of these limitations, the studies can’t tell us if CBD is effective for ongoing anxiety management.
A recent review found CBD had positive effects on anxiety, but these effects were seen in studies deemed to have problems with their methods, and not in studies that were more rigorously designed and conducted.
Similarly, a small Australian study (with no control group) demonstrated positive effects of CBD in young people with anxiety who had already tried other treatments. However, the authors stated more rigorous trials were still needed.
What’s more, there are recent case reports of acute psychosis arising from medicinal cannabis use. Taken together with the ambiguous evidence, the role for cannabinoids for anxiety remains far from clear.
How about sleep disorders?
The evidence for cannabis in the treatment of sleep disorders and insomnia is perhaps even more limited, with neither CBD or THC having shown clear benefits reducing the number of awakenings or time spent awake during the night, or improved sleep quality. That said, some people do report they have fewer symptoms of insomnia when using medicinal cannabis.
Similar to anxiety, many of the studies have major weaknesses in their study design that make it difficult to draw strong conclusions. There are also few studies that compare medicinal cannabis to proven treatments for sleep disorders and insomnia. This makes it hard to make recommendations for treatment based on the current research evidence.
THC can make you drowsy, and in the short term may help people fall asleep, or feel like they’re getting more sleep. But there are some important downsides to consider, too.
For example, if you take medicinal cannabis regularly to fall asleep your body can get used to it, making it harder to fall asleep without it. In the long term, medicinal cannabis can also affect the amounts of light and deep sleep a person will have, which can result in poorer sleep quality.
Read more: Cannabinoid products may reduce total sleep time in adults with insomnia
There is good evidence for some conditions
Some of the strongest evidence for medicinal cannabis products are for rare forms of epilepsy that don’t respond to existing treatments, and for treating symptoms associated with multiple sclerosis.
The only TGA-approved medicinal cannabis products are for these conditions.
There’s also evidence medicinal cannabis can help with chemotherapy-induced nausea and vomiting. Though as newer medications with fewer side-effects are now available, medicinal cannabis products aren’t considered first-line treatments.
Risks and side-effects
Common side-effects with THC in the short term include drowsiness, anxiety, dry mouth, nausea, vomiting and appetite changes. For some people, these effects reduce over time.
Some people with pre-existing health conditions such as schizophrenia, psychosis or heart conditions may be more prone to experiencing sideeffects.
An estimated one in four people using medical cannabis meet the criteria for dependence (known as cannabis use disorder). In the longer term, dependence appears more common with medical use, particularly when combined with non-medical use.
If you’re suffering with anxiety, sleep problems or chronic pain, and are wondering what treatments might be most effective for you, speak to your regular GP.
This article originally appeared on The Conversation.
About the Authors
-
Suzanne nielsen
Deputy Director, Monash Addiction Research Centre
Suzanne is an NHMRC Career Development Fellow. Her research has led to a greater understanding of how to identify and respond to prescription and over-the-counter drug-related problems. She's informed legislative change in Australia to reduce pharmaceutical drug harm, expanded overdose prevention with naloxone in primary care settings, and informed clinical guidelines on the use of opioid agonist treatment for prescribed opioids dependence. Her current research focuses on understanding how to improve identification of prescribed opioid use disorder, with the aim of reducing risks relating to prescribed opioid use through evidence-based treatment and prevention.
-
Myfanwy graham
NHMRC Postgraduate Scholar and Fulbright Alumna in Public Health Policy, Monash University Monash Addiction Research Centre
Myfanwy’s research focuses on the impact of drug policy on public health outcomes, the translation of research findings into clinical practice settings, and the use of real-world data to inform future policy decisions. She has completed consultancy work for the United Nations Office on Drugs and Crime, the World Health Organisation and the National Academy of Sciences, Engineering and Medicine. Prior to the award of a prestigious Fulbright Scholar role, Myfanwy was an Associate Investigator of the NHMRC-funded Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE), was the Principal Medicines Information Pharmacist of a state government-funded medicinal cannabis advisory service (2018-2022) and developed state government-funded medicinal cannabis prescribing guidance documents.
Other stories you might like
-
Is medicinal cannabis for chronic pain effective?
One in five people experience chronic pain. Here’s how likely you are to find relief with medicinal cannabis.
-
Shining a light on illicit drug use in regional Victoria
A new five-year study aims to build a broad picture of illicit drug use in regional Victoria, to better-understand the gaps in local health service planning.
-
Gaining insight into the potential of cannabis in combating viral infections
A review indicates that both cannabinoids and terpenes in cannabis show great promise as antivirals in laboratory research, and could be used to treat infections including COVID-19.
-
High pains drifter: Jury out on cannabis as a painkiller
Medical cannabis has been trumpeted in the media as a panacea for all manner of pain. But scientific evidence that it works is lacking.